Mao, Ming
Liu, Rui
Dong, Yi
Wang, Chaoqun
Ren, Yifei
Tian, Na
Tang, Shi
Hou, Tingting
Cong, Lin
Wang, Yongxiang http://orcid.org/0000-0002-8832-7301
Du, Yifeng
Qiu, Chengxuan
Funding for this research was provided by:
National Natural Science Foundation of China (81861138008)
Alzheimer's Association (AACSFD-22-922844)
National Key R&D Program of China Ministry of Sciences and Technology (2017YFC1310100)
Natural Science Foundation of Shandong Province (ZR2021MH005)
Academic Promotion Program of Shandong First Medical University (2019QL020, 2023ZL001)
Integrated Traditional Chinese and Western Medicine Program in Shandong Province (YXH2019ZXY008)
Brain Science and Brain-like Intelligence Technology Research Projects of China (2021ZD0201801, 2021ZD0201808)
Vetenskapsrådet (2017-05819, 2020-01574)
Swedish Foundation for International Cooperation in Research and Higher Education (CH2019-8320)
Karolinska Institutet
Karolinska Institute
Article History
Received: 7 June 2023
Accepted: 20 September 2023
First Online: 29 October 2023
Declarations
:
: The authors declared no conflict of interests.
: The MIND-China study was approved by the Ethics Committee at Shandong Provincial Hospital in Jinan, Shandong Province, China. MIND-China was registered in the Chinese Clinical Trial Registry (registration no.: ChiCTR1800017758). This study was conducted in full compliance with the ethical principles expressed in the Declaration of Helsinki.
: Prior to data collection, written informed consent was obtained from all participants or in case of persons with severe cognitive impairment, from a proxy.